Sandostatin inhibits development of medial proliferation of pulmonary arteries in a rat model of pulmonary hypertension |
| |
| Institution: | 1. Division of Endocrinology, Department of Internal Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China;2. Institute of Clinical Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China;1. Department of Pharmacology, Basic Medical School of Wuhan University, Wuhan 430071, China;2. Department of Orthopedic Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, China;3. Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan 430071, China;4. UMR 7561, CNRS-Université de Lorraine, Faculté de Médicine, Vandoeuvre-lès-Nancy, France;1. Division of Prevention and Community Health, National Center for Cardiovascular Disease, Fuwai Hospital, Peking Union Medical College, Chinese Academy of Medical Science, Beijing, China;2. Department of Cardiology, PLA General Hospital, Beijing 100853, China |
| |
| Abstract: | We investigated the effects of subcutaneous administration of 50 and 100 μg/kg/day of sandostatin on monocrotaline-induced medial proliferation of pulmonary arteries and right ventricular overload in rats. In a dosage of 100 μg/kg/day, sandostatin significantly reduced right ventricular systolic pressure, the mass ratio of the right ventricular free wall to the left ventricle, the right ventricular wall thickness, the right ventricular myofiber diameter, the percent medial pulmonary artery thickness, the percent area of smooth muscle cell, and proliferating cell nuclear antigen activity. Our results suggest that sandostatin inhibits development of medial proliferation of pulmonary arteries and right ventricular overload in a dosage of 100 μg/kg/day. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
